Literature DB >> 22428782

Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy.

A Bersano1, S Lanfranconi, C Valcarenghi, N Bresolin, G Micieli, P Baron.   

Abstract

Fabry disease is a multisystem, X-linked, lysosomal storage disorder caused by a mutation in the GLA gene on chromosome Xq22 resulting in alpha-galactosidase A enzyme (α-Gal A) deficiency. Neurological manifestations other than cerebrovascular accidents include small fibre neuropathy and dysautonomic disorders, which may be the presenting clinical features in a proportion of patients. An atypical disease onset may be misdiagnosed until the emergence of a more typical clinical picture, characterized by chronic renal and cardiac failure. Thus, neurologists should consider Fabry disease in differential diagnosis and provide an appropriate diagnostic work up. This review focuses on central and peripheral nervous system involving available diagnostic tools and diagnostic work up in Fabry disease. It also covers the most recent evidence regarding enzyme replacement therapy.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22428782     DOI: 10.1111/j.1600-0404.2012.01661.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  11 in total

Review 1.  Inherited neuropathies: an update.

Authors:  Anna Sagnelli; Giuseppe Piscosquito; Davide Pareyson
Journal:  J Neurol       Date:  2013-09-24       Impact factor: 4.849

Review 2.  Lysosomal Leukodystrophies Lysosomal Storage Diseases Associated With White Matter Abnormalities.

Authors:  Gustavo H B Maegawa
Journal:  J Child Neurol       Date:  2019-02-13       Impact factor: 1.987

Review 3.  [Genetics of ischemic stroke].

Authors:  A Gschwendtner; M Dichgans
Journal:  Nervenarzt       Date:  2013-02       Impact factor: 1.214

Review 4.  Sphingolipid lysosomal storage disorders.

Authors:  Frances M Platt
Journal:  Nature       Date:  2014-06-05       Impact factor: 49.962

Review 5.  Fabry Disease: Recognition, Diagnosis, and Treatment of Neurological Features.

Authors:  Michela Ranieri; Gloria Bedini; Eugenio Agostino Parati; Anna Bersano
Journal:  Curr Treat Options Neurol       Date:  2016-07       Impact factor: 3.598

Review 6.  Genetics of vascular dementia - review from the ICVD working group.

Authors:  M Arfan Ikram; Anna Bersano; Raquel Manso-Calderón; Jian-Ping Jia; Helena Schmidt; Lefkos Middleton; Benedetta Nacmias; Saima Siddiqi; Hieab H H Adams
Journal:  BMC Med       Date:  2017-03-06       Impact factor: 8.775

Review 7.  Identification of a Missense Mutation in the α-galactosidase A Gene in a Chinese Family with Fabry Disease.

Authors:  Yuan Wu; Hong Xia; Jinzhong Yuan; Hongbo Xu; Xiong Deng; Jun Liu; Hao Zhang; Hao Deng
Journal:  Curr Genomics       Date:  2018-01       Impact factor: 2.236

8.  Autophagy-lysosome pathway associated neuropathology and axonal degeneration in the brains of alpha-galactosidase A-deficient mice.

Authors:  Michael P Nelson; Tonia E Tse; Darrel B O'Quinn; Stefanie M Percival; Edgar A Jaimes; David G Warnock; John J Shacka
Journal:  Acta Neuropathol Commun       Date:  2014-02-14       Impact factor: 7.801

9.  Case report of concurrent Fabry disease and amyotrophic lateral sclerosis supports a common pathway of pathogenesis.

Authors:  Alexander M Beer; Johnathan Cooper-Knock; Sakina Fletcher; Sian Heledd Brown-Wright; T Pisharam Nandakumar; Pamela J Shaw
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2016-04-20       Impact factor: 4.092

10.  The GALA project: practical recommendations for the use of migalastat in clinical practice on the basis of a structured survey among Italian experts.

Authors:  Cristina Chimenti; Patrizia Nencini; Federico Pieruzzi; Sandro Feriozzi; Renzo Mignani; Maurizio Pieroni; Antonio Pisani
Journal:  Orphanet J Rare Dis       Date:  2020-04-07       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.